Bu nifer yr IPFR yn disgyn ers 2015 ac mae’r nifer fach yn 2018-19 (358) yn golygu y byddai’n anodd cyffredinoli neu dynnu casgliadau diffiniol am effaith y newidiadau a wnaethpwyd i’r broses IPFR. Eto i gyd mae’n dda gennyf adrodd y bu’r raddfa gymeradwyo am IPFR yn codi ers 2016-17, gan gyrraedd y lefel uchaf hyd yn hyn - 68% - yn 2018-19. Bu’r raddfa gymeradwyo am IPFR i feddyginiaethau yn cynyddu dros y bedair blynedd ddiwethaf nes cyrraedd y lefel uchaf hyd yn hyn - 71% - y llynedd. Mae’r raddfa gymeradwyo i driniaethau heblaw meddyginiaethau wedi amrywio dros amser ond y llynedd cafwyd y raddfa gymeradwyo uchaf hyd yn hyn – 66%. Yn ogystal ag IPFR, yn 2018-19, cafwyd 32 cais i barhau â’r cyllido, ar gyfer estyniadau i’r IPFR gwreiddiol. Cafwyd 28 i feddyginiaethau a chwech am driniaethau heblaw meddyginiaethau, sy’n nodi bod cleifion yn elwa o’r triniaethau y gofynnwyd amdanynt.
The number of IPFRs made has been falling since 2015 and the small number in 2018-19 (358) means it would be difficult to generalise or draw definitive conclusions about the impact of the changes made to the IPFR process. Nonetheless, I am pleased to report the approval rate for all IPFRs has been rising since 2016-17, reaching the highest level to date - 68% - in 2018-19. Similarly, the approval rate for medicine IPFRs has been increasing for the past 4 years reaching the highest level to date - 71% - last year. The approval rate for non-medicine IPFRs has varied over time but last year’s approval rate - 66% - is the highest to date. As well as IPFRs, in 2018-19, there were 34 continued funding requests, to fund extensions to original IPFRs. Of these, there were 28 for medicines and 6 for non-medicines, which indicate that patients were benefitting from the requested treatments.